SGLT-2 inhibitors and GLP-1 agonists associated with better mortality outcomes than DPP-4 inhibitors for type 2 diabetesApril 20, 2018
SGLT-2 or GLP-1 agonists were associated with lower mortality than DPP-4 inhibitors, placebo, or no treatment. Use of DPP-4 inhibitors was not associated with lower mortality than placebo or no treatment.
Crysvita is an antibody that blocks fibroblast growth factor 23 (FGF23), a hormone that causes phosphate urinary excretion and suppresses active vitamin D production by the kidney.
Investigators assessed the association between the cumulative dose of oral glucocorticoid treatment and expense associated with adverse events in patients with rheumatoid arthritis.
Study provides evidence that DPP-4 inhibitors are not associated with an increased risk of acute pancreatitis in older adults overall. The positive association observed in patients with CVD could be due to chance or bias but merits further investigation.
IPITA and EPITA held a workshop to develop consensus for a joint statement on the definition of function and failure of current and future forms of β-cell replacement therapy.
IDegLira provides an efficacious intensification option with noninferior glycemic control vs basal-bolus in patients with type 2 diabetes receiving 20 to 50 units of basal insulin with no renal impairment and HbA1c levels of 7% to 10%.
The composite significant kidney event end point was defined as the first occurrence of ≥30% decline in eGFR to an eGFR <60mL/min/1.73m2, initiation of dialysis or kidney transplant.
The Food and Drug Administration (FDA) has issued a discontinuation notice for Bydureon (exenatide extended-release; AstraZeneca) for injectable suspension Single Dose Trays.
The DURATION-7 study examined the effect of Bydureon or placebo as add-on therapy to insulin glargine, with or without metformin, in adults with T2D.
Bremelanotide, an investigational product, is thought to possess a novel mechanism of action, activating endogenous melanocortin pathways involved in sexual desire and response.
In combination with dietary and physical activity counseling, all semaglutide doses from 0.05-0.4 mg daily were tolerated and resulted in dose-related reductions in body weight among people with obesity without diabetes.
Treating Moderate to Severe Graves' Orbitopathy: Methylprednisolone Alone vs Combined With MycophenolateMarch 14, 2018
This study is the first to investigate the efficacy and safety of add-on mycophenolate to methylprednisolone for moderate to severe Graves' orbitopathy.
Prior authorization requirements are greater for proprotein convertase subtilisin/kexin type 9 inhibitors than for other cardiometabolic drugs.
After induction short-term intensive insulin therapy, metformin is superior to intermittent IIT for maintaining beta-cell function and glycemic control over 2 years.
Antithyroid drug exposure during the first trimester was associated with an increased risk for congenital malformations.
This is the first study to have validated a metformin dose adjustment as a function of the estimated glomerular filtration rate in patients with type 2 diabetes and chronic kidney disease.
Novo Nordisk has announced that the NovoFine 30G 8mm pen needle will be discontinued on or before April 30, 2018.
First trimester exposure to anytithyroid drugs was associated with a greater risk of congenital malformations, especially for pregnant women who were given prescriptions for methimazole or both methimazole and propylthiouracil.
Patients identified with increased insulin resistance following intra-articular corticosteroid injection or any systemic steroid treatment might need a special emphasis regarding management and followup.
For patients with type 2 diabetes undergoing non-cardiac surgery, premedication with liraglutide is associated with reduced median plasma glucose 1 hour postoperatively.
The Food and Drug Administration has accepted the New Drug Application for Azedra for the treatment of malignant, recurrent and/or unresectable pheochromocytoma and paraganglioma.
Steglatro is indicated as adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, and Steglujan is indicated as adjunct when treatment with both ertugliflozin and sitagliptin are appropriate.
Study aimed to evaluate the benefits of levothytoxine treatment on pregnancy outcomes in subclinical hypothyroid pregnant women who are negative for thyroid peroxidase antibody.
Study sought to determine the optimal dosing of linagliptin for the treatment of children with type 2 diabetes.
A randomized controlled trial evaluated whether treatment intensification with biphasic insulin aspart 30 improved glycemic control in patients with type 2 diabetes.
Representatives from multiple associations and societies have issued a new report standardizing clinically meaningful outcome measures for type 1 diabetes, beyond using HbA1c testing.
Patients with diabetes taking saxagliptin, sitagliptin, second-generation sulfonylureas, pioglitazone, and long-acting insulin were assessed for the risk of acute myocardial infarction.
Semaglutide, a once-weekly GLP-1 receptor agonist, demonstrated clinically significant reductions in HbA1c among adults with type 2 diabetes.
Study assessed the effects of sotagliflozin vs placebo with respect to glycemic control and the occurrence of severe hypoglycemia and diabetic ketoacidosis among adults with type 1 diabetes.
Once-weekly administration of extended-release exenatide in patients with T2D at a wide range of cardiovascular risk appeared not to cause an increase in their overall cardiovascular risk.
Endocrinology Advisor Articles
- Clinicians May Be Overtreating Older Patients With Diabetes
- Obesity Risk in Infants Born to Women With Diabetes
- Increased Risk for Mortality in People With Diabetes, CHD Taking Beta-Blockers
- Autism Does Not Affect Metabolic Control in Type 1 Diabetes
- Nivolumab Associated With Thyroiditis in Patients With Cancer
- Gender-Related Association Between Physical Activity, Psychological Status in T2D
- Adverse Neurodevelopmental and Mental Health Outcomes in PCOS
- HbA1c Variability Predicts All-Cause Mortality in Type 2 Diabetes
- Choroidal Thickness Changes in Patients With Untreated Diabetes
- Pre-Pregnancy Fitness Lowers Gestational Diabetes Risk